HK Stock Market Move | GENSCRIPT BIO (01548) Afternoon decline expands by over 11% Legend Biotech's overnight stock price plunges by 7%

GENSCRIPT BIO (01548) plunged by more than 11% in the afternoon, with a drop of 11.07% to HK$13.41, with a transaction amount of HK$3.07 billion as of the time of writing. On the news front, GENSCRIPT BIO's joint venture Legend Biotech saw its stock price drop by over 7% overnight. According to media reports, at the 2025 American Society of Hematology (ASH) Annual Meeting, Kite Pharma, a subsidiary of Gilead Sciences, announced the latest clinical data for the next-generation CAR-T therapy anito-cel. This candidate drug for multiple myeloma showed a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety. Huatai's previous research report pointed out that Legend Biotech's losses have narrowed, and the group's blueprint is clear. CARVYKTI achieved sales of $1.332 billion in the first three quarters, with Q3 sales of $524 million; Legend Biotech incurred a net loss of $266 million in the first three quarters, with a net loss of $40 million in Q3, both significantly reduced losses year-on-year and quarter-on-quarter. Expecting orderly growth/profit turnaround for GENSCRIPT BIO's various business segments.